What can we learn from the three megatrials using anticoagulants in severe sepsis?

Shock

Volumn 22, Issue 6, 2004, Pages 508-512

  Iba, Toshiaki ^a   Kidokoro, Akio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticoagulants; AT; rTFPI; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DANAPAROID; HEPARIN; PLACEBO; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOMODULIN;

ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BINDING SITE; BLEEDING; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG USE; ENDOTHELIUM CELL; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; LOW DRUG DOSE; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOGENESIS; REVIEW; SEPSIS; VASCULAR ENDOTHELIUM;

ANTICOAGULANTS; CLINICAL TRIALS; HEPARIN; HUMANS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 9644302620     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000145934.24344.64     Document Type: Review

References (40)

1. Esmon CT, Taylor FB Jr, Snow TR: Inflammation and coagulation: linked processes potentially regulated through a common pathway radiated by protein C. Thromb Haemost 66:160-165, 1991.
2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: For the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
3. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM: KyberSept Trial Study Group: High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 286:1869-1878, 2001.
4. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA: OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-247, 2003.
5. Crowther MA, Marchall JC: Continuing challenges of sepsis research. JAMA 286:1894-1896, 2001.
6. Opal SM: Clinical trial design and outcomes in patients with severe sepsis. Shock 20:295-302, 2003.
7. Freeman BD, Zehnbauer BA, Buchman TG: A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5-9, 2003.
8. Macias WL, Sasheygi A, Xu D: A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:582-583, 2003.
9. Freeman BD: A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis: reply. Shock 20:583-584, 2003.
10. Oelschlager C, Romisch J, Staubitz A, Stauss H, Leithauser B, Tillmanns H, Holschermann H: Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 99:4015-4020, 2002.
11. Horie S, Ishii H, Kazama M: Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 59:899-904, 1990.
12. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endolhelium and is neuroprotective. Nat Med 9:338-342, 2003.
13. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276:11199-11203, 2001.
14. Iba T, Kidokoro A: High dose antithrombin therapy for sepsis: mechanism of action. Shock 18:389-394, 2002.
15. Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun TC, Creasey AA, Hinshaw LB: Recombinant E. coli derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram negative model of septic shock. Circ Shock 44:126-137, 1995.
16. Opal SM: Therapeutic rationale for antithrombin in sepsis. Crit Care Med 28: S34-S37, 2000.
17. Pulletz S, Lehmann C, Volk T, Schmutzler M, Ziemer S, Kox WJ, Scherer RU: Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 28:2881-2886, 2000.
18. 243, of the third Kunitz domain is a heparin-binding site. Biochemistry 34:5725-5735, 1995.
19. Anti-Infective Advisory Committee: FDA briefing document: drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris. BLA#125029/0. Rockville, Md: Food and Drug Administration, September 12. 2001. (Accessed September 6, 2002, at http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 379b1_02_FDAbriefing.pdf).
20. Iba T, Kidokoro A, Yagi Y: The role of the endothelium in changes in procoagulant activity. J Am Coll Surg 187:321-329, 1998.
21. Dhainaut JF, Van SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT, PROWESS Sepsis Study Group: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90:642-653, 2003.
22. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A: Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536-1542, 1993.
23. Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I: Predictive value of antithrombin 111 and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 30:271-275, 2002.
24. Mesters RM, Heiterbrand J, Utterback BG, Van B, Chao YB, Fernandez JA, Griffin JH, Hartman DL: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28:2209-2216, 2000.
25. Shimura M, Wada H, Nakasaki T, Hiyoyama K, Mori Y, Nishikawa M, Deguchi H, Deguchi K, Gabazza EC, Shiku H: Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 60:94-98, 1999.
26. Creasey AA: New potential therapeutic modalities: tissue factor pathway inhibitor. Sepsis 3:173-182, 1999.
27. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166:1197-1205, 2002.
28. Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347:1027-1030, 2002.
29. Opal SM, Cross AS: Clinical trials for severe sepsis: past failures and future hopes. Infect Dis Clin North Am 13:285-298, 1999.
30. Freeman BD, Zehnbauer BA, Buchman TG: A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5-9, 2003.
31. Ilias W, List W, Decruyenaere J, Lignian H, Knaub S, Schindel F, Keinecke HO, Heinrichs H, Thijs LG: Antithrombin III in patients with severe sepsis: a pharmacokinetic study. Intensive Care Med 26:704-715, 2000.
32. Abraham E: Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 28(suppl 9):S31-S33, 2000.
33. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, Zwingelstein C, Percell S, Shu V, Leighton A, Creasey AA: Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multi-center, randomized, placebo-controlled, single-bind, dose escalation study. Crit Care Med 29:2081-2089, 2001.
34. Davidson BL, Geerts WH, Lensing AWA: Low-dose heparin for severe sepsis. N Engl J Med 347:1036-1037, 2002.
35. Freebairn R, Ramsay S, Gomersall C: Low-dose heparin for severe sepsis. N Engl J Med 348:1185-1186, 2003.
36. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM: for the Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858-873, 2004.
37. Iba T, Kidokoro A, Fukunaga M, Fuse S, Suda M, Kunitada S, Hara T: Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat. Shock 17:159-162, 2002.
38. Moran JF: New Therapeutic Agents in Thrombosis and Thrombolysis. 2nd Edition. Shock 20:195-196, 2003.
39. Danhof M, de Boer A, Magnani HN, Stiekema JC: Pharmacokinetic considerations on orgaran (ORG10172) therapy. Haemostasis 22:73-78, 1992.
40. Iba T, Kidokoro A, Fukunaga M, Ogasawara T, Kato H: Antithrombin / danaparoid sodium combination therapy is effective for organ dysfunction induced by endotoxin. J Jpn Soc Intensive Care Med 11:193-199, 2004.